Three-drug combo for metastatic colorectal cancer as second treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- You have metastatic colorectal cancer (cancer that has spread) that is the most common type (adenocarcinoma)
- You have already received first-line chemotherapy with oxaliplatin (like FOLFOX or XELOX) and it stopped working
- Your blood counts and liver/kidney function are within normal limits
- You are able to take pills by mouth and have no active bleeding or need for blood transfusions in the last 2 weeks
- You have not had irinotecan before, or if you did, it was only as maintenance therapy (not while the cancer was growing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
This trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and who have already had surgery to remove as much cancer as possible. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.